3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
7
Nivolumab
3
atezolizumab
2
Aminolevulinic Acid
2
testosterone enanthate
1
regorafenib
1
osimertinib
1
nanocis
1
fluoroazomycin arabinoside
1
fludarabine
1
cobimetinib
1
cabozantinib
1
avelumab
1
aldesleukin
1
aflibercept
1
Vorinostat
1
Therapeutics
1
Technetium-99
1
Solutions
1
Red Light
1
Radiation, Ionizing
1
Proton Pump Inhibitors
1
Paclitaxel
1
Observation
1
NEO212
1
Metformin
1
Ipilimumab
1
Interleukin-2
1
Infracyanine green
1
Indocyanine Green
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
nanocis
×
Gynecologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled